Loading...
XNASPROCW
Market cap189mUSD
Jan 08, Last price  
0.05USD
1D
0.00%
1Q
108.33%
IPO
-85.72%
Name

Procaps Group SA

Chart & Performance

D1W1MN
XNAS:PROCW chart
P/E
0.13
P/S
0.01
EPS
0.38
Div Yield, %
0.00%
Shrs. gr., 5y
Rev. gr., 5y
%
Revenues
410m
+0.04%
324,792,000331,467,000409,742,000409,920,000
Net income
43m
P
-17,013,000-10,447,000-100,863,00042,540,000
CFO
14m
-62.19%
68,286,00070,920,00037,303,00014,106,000

Profile

Procaps Group S.A. develops, produces, and markets pharmaceutical solutions worldwide. The company formulates, manufactures, and markets branded prescription drugs in various therapeutic areas, including feminine care products, pain relief, skin care, digestive health, growth and development, cardiology, vision care, central nervous system, and respiratory. It also provides drugs for hospital use, such as antibiotic, blood clot, personal protective equipment, immunosuppressant, oncology, and analgesics products. In addition, the company offers over-the-counter (OTC) consumer healthcare products through a portfolio on approximately eight therapeutic areas, including gastrointestinal, skin care, cough and cold, analgesics, urological, vitamins, minerals, and supplements in the categories of antibiotics, anti-infective, anti-parasitic, cardiovascular, feminine care, cutaneous antimycotic, pain killers, gastro intestinal, hormonals, metabolic, endocrine, nervous system, ophthalmic, osteoarticular, respiratory, diet supplements, and vitamins and minerals. Further, it provides blood glucose meters, telemonitoring products, oral anti-diabetics products, cosmeceuticals, insulin delivery systems, and other diabetes solutions; and contract drug development and manufacturing services to third party pharmaceutical companies, specializing in soft gelatin capsule technologies. The company was founded in 1977 and is based in Luxembourg, Luxembourg.
IPO date
Dec 09, 2019
Employees
5,500
Domiciled in
LU
Incorporated in
LU

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFY
2022‑122021‑122020‑122019‑12
Income
Revenues
409,920
0.04%
Cost of revenue
372,561
Unusual Expense (Income)
NOPBT
37,359
NOPBT Margin
9.11%
Operating Taxes
10,170
Tax Rate
27.22%
NOPAT
27,189
Net income
42,540
-142.18%
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
257,525
Long-term debt
53,549
Deferred revenue
Other long-term liabilities
57,460
Net debt
266,356
Cash flow
Cash from operating activities
14,106
CAPEX
(31,575)
Cash from investing activities
(28,828)
Cash from financing activities
(13,627)
FCF
(3,946)
Balance
Cash
43,003
Long term investments
1,715
Excess cash
24,222
Stockholders' equity
(379,555)
Invested Capital
714,939
ROIC
3.72%
ROCE
10.89%
EV
Common stock shares outstanding
101,110
Price
5.25
-46.15%
Market cap
530,828
-44.53%
EV
796,246
EBITDA
54,203
EV/EBITDA
14.69
Interest
25,762
Interest/NOPBT
68.96%